Loading articles...
Alzheimer DiseaseGlucosamine/Chondroitin Tied to Faster AD Progression
A recent analysis indicates that regular use of glucosamine and chondroitin may accelerate Alzheimer's disease progression in susceptible individuals.
Alzheimer DiseaseAD Biomarkers Linked to Worse Cognition in Midlife Adults
Elevated Alzheimer's disease biomarkers in midlife adults are associated with poorer cognitive performance, indicating preclinical disease progression.
Alzheimer DiseaseWhy New Alzheimer's Drugs Make Brains Bleed?
ARIA — amyloid-related imaging abnormalities — affects up to 24% of patients on anti-amyloid therapy. APOE4 genotyping, MRI monitoring protocols, severity-graded management, and the anticoagulation dilemma: a practical guide to navigating the risk.
Alzheimer DiseaseTargeting Tau Inflammation And Alzheimer's Metabolism
Amyloid clearance is only one part of the Alzheimer's story. Why tau remains the closer correlate of cognitive decline, what the TREM2 biology tells us about microglia, what the GLP-1 signal means, and how platform trials are moving toward multi-target comb...
Alzheimer DiseasePreventing 45 Percent Of Dementia Cases
The Lancet Commission 2024 estimates 45% of dementia is preventable. SPRINT-MIND showed 19% MCI reduction from intensive blood pressure control. FINGER showed 25% better cognitive scores with multi-domain lifestyle intervention. ACHIEVE showed 48% slowing i...
Alzheimer DiseaseThe Amyloid Hypothesis, Finally Validated?
After two decades of high-profile failures, lecanemab and donanemab have produced the first positive phase 3 trials in Alzheimer's disease. We examine the CLARITY-AD and TRAILBLAZER-ALZ 2 data, the clinical meaningfulness debate, and what the approvals actu...
Alzheimer DiseaseAmyloid Therapies Show Limited Cognitive Benefit in Alzheimer's
Amyloid-beta targeting therapies for Alzheimer's disease demonstrate modest effects on cognitive decline, with clinical significance remaining uncertain.
Alzheimer DiseaseAmyloid Therapies Show Limited Cognitive Benefit in AD
Current pharmacological therapies for Alzheimer's disease offer symptomatic relief but do not halt or reverse disease progression.
Alzheimer DiseasePARP1 Deficiency Reduces Amyloid Pathology in Familial AD Model
New preclinical work links PARP1 deficiency to reduced amyloid burden and cognitive preservation in a familial Alzheimer's model.
Alzheimer DiseaseGut Microbiota Signal the Brain via the Vagus Nerve: What GPs Should Know
The gut-brain axis operates partly through vagal afferent neurons. Here is what the established mechanistic evidence means for everyday practice.